Antigen treatment with glutamic acid decarboxylase 65 formulated with alum did not halt the loss of stimulated serum C-peptide or bring about immunologic tolerance in type 1 diabetes, a 15-month study of children and young adults aged 10 years to 20 years found. Researchers reported no differences among two GAD-alum regimens and placebo in mean daily insulin dose, glycated hemoglobin levels or other outcomes. The findings appear in the New England Journal of Medicine.

Related Summaries